The PRISM 3 clinical research trial is for patients who have had a recurrence of Clostridium difficile infection (CDI or C. diff). The trial will evaluate the safety and effectiveness of CP101 (the study drug) to prevent recurrence of CDI compared against placebo.
You may qualify if you*:
Are 18 years of age or older
Are experiencing recurrent CDI
Have responded to CDI antibiotic therapy for the most recent CDI episode
Do not have a history or diagnosis of inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS)
*Other criteria will apply
We are working with doctors at medical facilities across the United States to conduct the PRISM 3 trial for patients with recurrent Clostridium difficile infection.
If you or someone you know are interested in participating in the trial, please use the tool below to find the contact information of participating hospitals near you. If you do not find a participating hospital near you, please contact us at PRISM3trial@finchtherapeutics.com for more information.